Allergy/Imm Medical News about rituximab

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy
Rheumatology International, 07/08/09

Sanchez-Ramon S et al. - The authors report on a 44-year-old woman affected by dermatopolymyositis resistant to conventional therapies who experienced long-term clinical improvement and remission after treatment with intravenous polyvalent immunoglobulin in a weekly schedule followed by rituximab therapy.

<< Previous
Phenotype of atopic dermatitis subjects with a history of eczema...

Next >>
Apo material as a trigger for inflammation in systemic lupus...

Treatment of adult inflammatory myositis with rituximab: An emerging therapy for refractory patients
Journal of Clinical Rheumatology (JCR), 10/08/09 Relevance Score: 90%

Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection
Nephrology, 10/07/09 Relevance Score: 89%

Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: Effects of rituximab
Annals of Oncology, 11/10/09 Relevance Score: 88%

Prevention of hepatitis B virus reactivation under rituximab therapy
Immunotherapy, 11/06/09 Relevance Score: 88%

Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
Annals of Oncology, 11/06/09 Relevance Score: 87%